In this CME activity Elias Jabbour, MD, provides his perspectives on key posters presented at the American Society of Hematology's 60th Annual Meeting & Exposition held in San Diego,California, on the treatment of patients with acute lymphoblastic leukemia (ALL). We invite you to learn more about the current and emerging standards of care, as well as safety and efficacy data from the select clinical trials, in patients with acute lymphoblastic leukemia.

faculty

Elias Jabbour, MD
Elias Jabbour, MD
Associate Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Content Areas

  • CD19-positive ALL
  • A bispecific T-cell engager antibody
  • Antibody drug conjugate
  • Low-intensity chemotherapy
  • Philadelphia chromosome-negative ALL
  • Minimal residual disease
  • Veno-occlusive disease
  • Allogeneic stem-cell transplantation

Cme credit

Available Credit: 1.00 AMA PRA Category 1 Credit™.
Opens: April 30, 2019
Expires: April 29, 2020
Target Audience: Hematologist/Oncologists
Other Health Care Providers

This activity is supported by educational funding provided by Amgen.
Enter your information to begin.

Target Audience

This activity is intended for hematologist-oncologists and other clinicians interested in the management of patients with acute lymphoblastic leukemia (ALL).